Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner

1 .- 69 . (canceled)

70 . A polypeptide comprising a first domain and a second domain, wherein the first domain comprises a first amino acid sequence that possesses at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, and wherein the first domain is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, and wherein the second domain comprises a second amino acid sequence capable of binding to a peptide on a tumor cell, wherein the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.

71 . The polypeptide of claim 70 , wherein the second domain is an antibody.

72 . The polypeptide of claim 70 , wherein the peptide is selected from the group consisting of ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH30.

73 . The polypeptide of claim 70 , wherein the tumor cell is selected from the group consisting of a breast cancer cell, a prostate cancer cell, a melanoma cell, an ovarian cancer cell, a gastric cancer cell, a glioblastoma cell, a neuroblastoma cell, a lung cancer cell, a lymphoma cell, a leukemia cell, a colon cancer cell, a renal cell carcinoma, a pancreatic cancer cell, and a hepatocellular carcinoma cell.

74 . The polypeptide of claim 70 , wherein the first amino acid sequence possesses at least 90% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 90% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and at least 90% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.

75 . The polypeptide of claim 70 , wherein the first amino acid sequence possesses at least 80% homology to SEQ ID NOs: 1, 2 or 3.

76 . A pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable excipient, wherein the polypeptide comprises a first domain and a second domain, wherein the first domain comprises a first amino acid sequence that possesses at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, and wherein the first domain is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, and wherein the second domain comprises a second amino acid sequence capable of binding to a peptide on a tumor cell, wherein the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.

77 . The pharmaceutical composition of claim 76 , wherein the second domain is an antibody.

78 . The pharmaceutical composition of claim 76 , wherein the peptide is selected from the group consisting of ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH30.

79 . The pharmaceutical composition of claim 76 , wherein the tumor cell is selected from the group consisting of a breast cancer cell, a prostate cancer cell, a melanoma cell, an ovarian cancer cell, a gastric cancer cell, a glioblastoma cell, a neuroblastoma cell, a lung cancer cell, a lymphoma cell, a leukemia cell, a colon cancer cell, a renal cell carcinoma, a pancreatic cancer cell, and a hepatocellular carcinoma cell.

80 . The pharmaceutical composition of claim 76 , wherein the first amino acid sequence possesses at least 90% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 90% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and at least 90% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.

81 . The pharmaceutical composition of claim 76 , wherein the first amino acid sequence possesses at least 80% homology to SEQ ID NOs: 1, 2 or 3.

82 . The pharmaceutical composition of claim 76 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a diluent, a binder, a filler, a buffering agent, a pH modifying agent, a disintegrant, a dispersant, a preservative, a lubricant, taste-masking agent, a flavoring agent, and a coloring agent.

83 . A method for treating a tumor in a subject in need thereof comprising administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable excipient, wherein the polypeptide comprises a first domain and a second domain, wherein the first domain comprises a first amino acid sequence that possesses at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, and wherein the first domain is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, and wherein the second domain comprises a second amino acid sequence capable of binding to a peptide on a tumor cell, wherein the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell.

84 . The method of claim 83 , wherein the second domain is an antibody.

85 . The method of claim 83 , wherein the peptide is selected from the group consisting of ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH30.

86 . The method of claim 83 , wherein the tumor cell is selected from the group consisting of a breast cancer cell, a prostate cancer cell, a melanoma cell, an ovarian cancer cell, a gastric cancer cell, a glioblastoma cell, a neuroblastoma cell, a lung cancer cell, a lymphoma cell, a leukemia cell, a colon cancer cell, a renal cell carcinoma, a pancreatic cancer cell, and a hepatocellular carcinoma cell.

87 . The method of claim 83 , wherein the first amino acid sequence possesses at least 90% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 90% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and at least 90% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.

88 . The method of claim 83 , wherein the first amino acid sequence possesses at least 80% homology to SEQ ID NOs: 1, 2 or 3.

89 . The method of claim 83 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a diluent, a binder, a filler, a buffering agent, a pH modifying agent, a disintegrant, a dispersant, a preservative, a lubricant, taste-masking agent, a flavoring agent, and a coloring agent.

90 . The method of claim 83 , wherein the step of administering is performed orally or otherwise peripherally.

91 . The method of claim 83 , wherein the step of administering is peripherally and is selected from the group consisting of intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository.

92 . The method of claim 83 , wherein the step of administering is performed by subcutaneous, intramuscular, or intravenous injection.